This technology is an epigenetic editing platform that enables rapid, efficient and selective methylation of targeted DNA regions.
DNA methylation is a fundamental epigenetic language that regulates a vast array of biological processes by selectively turning genes on or off, and abnormal methylation is implicated in numerous human diseases. Despite their promise, current CRISPR-based DNA methylation editors are still constrained by slow editing kinetics, off-target activity, and cytotoxicity, which substantially limit their broad applicability.
This technology is a DNA methylation editing platform, CRISPR-IMPRINT, that embeds an engineered bacterial cytosine methyltransferase in the CRISPR-dCas9 system. It enables rapid, efficient methylation editing within hours, while reducing off-target activity and cytotoxicity compared with existing technologies. In proof-of-concept studies, CRISPR-IMPRINT selectively methylated a pathological disease allele, leading to reduced disease-relevant phenotypes. This technology enables basic epigenetic research and offers potential for therapeutic development.
This technology has been validated in vitro with human cell lines.
Patent Pending
IR CU26076
Licensing Contact: Joan Martinez